



HAL
open science

Young children formula consumption and iron deficiency at 24 months in the general population: A national-level study

Anne-Sylvia Sacri, Alain Bocquet, Mariane de Montalembert, Serge Hercberg, Laurent Gouya, Béatrice Blondel, Amandine Ganon, Pascale Hebel, Catherine Vincelet, Franck Thollot, et al.

► To cite this version:

Anne-Sylvia Sacri, Alain Bocquet, Mariane de Montalembert, Serge Hercberg, Laurent Gouya, et al.. Young children formula consumption and iron deficiency at 24 months in the general population: A national-level study. *Clinical Nutrition*, 2021, 40, pp.166 - 173. 10.1016/j.clnu.2020.04.041 . hal-03493162

HAL Id: hal-03493162

<https://hal.science/hal-03493162v1>

Submitted on 2 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Young children formula consumption and iron deficiency at 24 months in the general**
2 **population: a national-level study**

3

4 **Authors' full name and academic degrees:**

5 Anne-Sylvia Sacri, MD, PhD ^{a,b}; Alain Bocquet, MD ^{c,d}; Mariane de Montalembert, MD,
6 PhD ^{a,b}; Serge Hercberg, MD, PhD ^{e,f}; Laurent Gouya, MD, PhD ^g; Béatrice Blondel, PhD ^a;
7 Amandine Ganon, Pharm D ^h; Pascale Hebel, PhD ⁱ; Catherine Vincelet, MD ^j; Franck
8 Thollot, MD ^k; Massimiliano Rallo, MD ^l; Piotr Gembara, MD ^m; Corinne Levy, MD ^{c,n,o};
9 Martin Chalumeau, MD, PhD ^{a,b}

10

11 **Authors' affiliations:**

12 ^a Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité, Obstetrical,
13 Perinatal and Pediatric Epidemiology Research team (EPOPé), Inserm UMR 1153; Labex
14 GR-Ex; Paris Descartes University, France

15 ^b Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants malades
16 hospital, AP-HP; Paris Descartes University; Paris, France

17 ^c Association Française de Pédiatrie Ambulatoire (AFPA), Talence, France

18 ^d Comité de nutrition de la Société Française de Pédiatrie, Paris, France

19 ^e Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité, Nutritional
20 Epidemiology Research Team (EREN), Inserm UMR 1153, Paris Descartes University,
21 Sorbonne Paris Cité, France

22 ^f Département de Santé Publique, AP-HP, Hôpital Avicenne, Bobigny

23 ^g Centre de recherche sur l'inflammation, Inserm UMR 1149, Université Paris Diderot ; ERL
24 CNRS 8252, Faculté de Médecine site Bichat, Paris, France

25 ^h Laboratoire CERBA, Saint-Ouen l'Aumône, France

26 ⁱ Centre de Recherche pour l'Etude et l'Observation des Conditions de vie (CREDOC), Paris,
27 France

28 ^j Centre régional de coordination des dépistages des cancers Ile-de-France, Lieusaint, France

29 ^k Cabinet de pédiatrie, 4 Rue Parmentier, Essay Les Nancy, France

30 ^l Cabinet de pédiatrie, 3 Rue de la Béraudière, Nantes, France

31 ^m Cabinet de pédiatrie, 4 Avenue Pierre Coulon, Vichy, France

32 ⁿ Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), Saint-Maur des
33 Fossés, France

34 ^o Université Paris Est, IMRB- GRC GEMINI, 94000 Créteil, France

35

36

37 **Short title:** Iron-fortified formula use and iron deficiency

38

39 **Corresponding author:**

40 Anne-Sylvia Sacri, Inserm UMR1153, Épidémiologie Périnatale, Obstétricale et Pédiatrique
41 (ÉPOPÉ). Maternité de Port Royal, 53 avenue de l'Observatoire, 75014 PARIS, France.

42 Phone: +33142345580. Fax: +33143268979. E-mail: anne-sylvia.sacri@inserm.fr

43

44

45 **Abstract (286/300 words)**

46 **Background and aims:** Iron deficiency (ID) is considered the most frequent micronutrient
47 deficiency in industrialized countries where strategies for its primary prevention vary widely
48 and are insufficiently evaluated. We aimed to study the effectiveness for iron status of a
49 national iron deficiency prevention strategy based on recommendations for young-child
50 formula (YCF) use after age 12 months, taking into consideration other sources of iron and
51 the family's socio-economic status.

52 **Methods:** In a cross-sectional observational study conducted in primary care pediatrician
53 offices throughout France from 2016 to 2017, infants aged 24 months were consecutively
54 included for a food survey and blood sampling. Associations between YCF consumption and
55 serum ferritin (SF) level were studied by multivariable regression after adjustment on
56 sociodemographic, perinatal and dietary characteristics, notably other intakes of iron.

57 **Results:** Among the 561 infants analyzed, the ID prevalence was 6.6% (37/551; 95%
58 confidence interval [CI] 4.7-9.0). Daily iron intake excluding YCF and total daily iron intake
59 including YCF were below the 5-mg/day recommended average requirements for 63% and
60 18% of children, respectively. ID frequency was significantly decreased (or SF level was
61 independently higher) with any YCF consumption since age 10 months (odds ratio 0.15, 95%
62 CI 0.07-0.31), current YCF consumption at age 24 months (median SF level 29 vs 21 $\mu\text{g/L}$ if
63 none), prolonged YCF consumption (28 $\mu\text{g/L}$ if > 12 months vs 17 $\mu\text{g/L}$ if none), and
64 increasing daily volume of YCF consumed at age 24 months from a small volume (e.g., 29
65 $\mu\text{g/L}$ if <100 mL/day vs 21 $\mu\text{g/L}$ if none).

66 **Conclusions:** Current or past YCF use was independently associated with a better iron status
67 at age 24 months than non-use. The strategy recommending YCF use at weaning after age 12
68 months seems effective in the general population.

69 **ClinicalTrials.gov identifier:** NCT02484274

70

71 **Keywords:** Iron deficiency; primary prevention; young-child formula; socioeconomic factors,

72 effectiveness; nationwide cohort study

73 **Introduction**

74 Iron deficiency (ID)¹ is considered the most frequent micronutrient deficiency worldwide,
75 including in industrialized countries, and is strongly suspected to be associated with adverse
76 short- and long-term neurocognitive effects when it occurs in neonates and infants [1]. In this
77 context, ID is a target of various primary preventive strategies supported by medical societies
78 and public health authorities, based on advice to parents for consumption of naturally iron-
79 rich foods during complementary feeding, iron fortification (e.g., formula or cereals) or iron
80 supplementation (drops) in their children [2-4]. In some countries like France, the preventive
81 strategy involves both parental education related to complementary feeding and the
82 recommendation for consumption of iron-fortified formulas (IFFs) at breastfeeding cessation
83 [5]. IFFs after age 6 months include “follow-on formulas” and “young-child formulas”
84 (YCFs, sometimes inadequately called “growing-up formula”) between age 6 and 10-12
85 months and after 10-12 months, respectively, to help to ensure the recommended average
86 requirement (AR) of 5 mg/day at this age [5, 6]. The European Food Security and Authority
87 (EFSA) does not recommend YCF as the main source of iron after age 12 months and has
88 criticized YCF-based strategies given the lack of evidence supporting their superiority as
89 compared with balanced diet strategies [7, 8]. In some industrialized countries, balanced diets
90 were recently shown to be rarely achieved at this age at the population level [9, 10].

91 The efficacy of IFFs has been evaluated by eight clinical trials, seven of which found a
92 statistically significant effect of IFFs use on iron status [11-17]. The efficacy of IFFs seems
93 well established at the scale of randomized trials, but this conclusion cannot be extrapolated
94 to their effectiveness, notably after age 12 months, at the population level. Indeed, the ability
95 of IFF-based strategies to reach disadvantaged families (with low economic and/or education

¹ **Abbreviations:** AR: average requirements; EFSA: European Food and Security Authority; ID: iron deficiency; IFF: iron-fortified formula; SF: serum ferritin; YCF: young children formula.

96 level) [18-21], who are at greatest risk of ID [2-4, 22], is poorly known and should be
97 evaluated. Moreover, to be reliable, such demonstration must take into consideration between-
98 country and between-region variability in iron intake from non-dairy food. Thus, the
99 evaluation of the effectiveness of IFF-based prevention strategies requires large populations
100 with a diversified recruitment collecting sociodemographic, biological and dietary data. Only
101 three studies with a closely approaching design are available and were performed in Ireland,
102 The Netherlands, and the United Kingdom [23-25]. They all found a protective effect of YCF
103 on iron status at age 12 to 24 months (e.g., adjusted odds ratio [OR] for ID was 5.5 for lack of
104 use of YCF [24]). However, these studies had limitations that prevent definitive conclusions
105 on the effectiveness of YCF-based strategies: selection bias (single-center recruitment [25],
106 children requiring surgery [24]), strong attrition [23, 25], dietary survey not following EFSA
107 recommendations [24], and/or lack of multivariate analyses to take into consideration socio-
108 economic status or non-dairy iron intake [23].

109 A non-biased evaluation of the independent effect of YCF at the national level is
110 needed to produce evidence to discourage or support YCF-based strategies after age 12
111 months versus other strategies for ID primary prevention. Here we aimed to evaluate the
112 effectiveness of a strategy for ID prevention based on the recommendation of YCF use after
113 age 12 months at a national level by analyzing its association with iron status in children aged
114 24 months, taking into account other sources of iron and the family's socio-economic status.

115

116 **Methods**

117 *General methodology*

118 We conducted a cross-sectional observational study in primary care paediatric private
119 practices throughout France from January 2016 to December 2017, named the CARMA
120 study. The signed consent from at least one parent was obtained before inclusion. The study

121 protocol was approved by local ethics and administrative authorities (CPP IDF III no. 3295)
122 and was registered (ClinicalTrials.gov identifier: NCT02484274). We used the Strengthening
123 the Reporting of Observational Studies in Epidemiology (STROBE) guidelines to report this
124 study (**Supplemental Table 1**).

125

126 *Participant selection*

127 Investigators were recruited from the directory of the French Ambulatory Pediatricians
128 Association (the national association of primary care pediatricians, $n \approx 1600$). Invitations to
129 participate were sent to all pediatricians. Among the respondents, a selected sample of about
130 120 pediatricians stratified on the 21 French continental regions was recruited to take in
131 consideration the between-region variability. Investigator recruitment was secondarily
132 extended to all members of the association given difficulties in recruiting participants in this
133 complex study. This recruitment in primary care pediatrician offices and different regions of
134 the country aimed at including infants from the general ambulatory population at a national
135 level. Each pediatrician was asked to include 10 consecutive children, aged 22 to 26 months,
136 usually living in France (**Supplemental Figure 1**), who had health insurance coverage, and
137 were not known to be affected by at least one of the following diseases that may affect iron
138 metabolism: transfusion(s) since birth, celiac disease, inflammatory bowel disease, cystic
139 fibrosis, other enteropathy (except allergy to cow's milk protein), enteral nutrition of more
140 than 15 days in the last 6 months, chronic hemolytic diseases, chronic renal failure,
141 hemophilia, hemochromatosis, malignant diseases and lead poisoning.

142

143 *Data collection*

144 The study phases are described in detail in **Supplemental Methods**. In summary, current
145 sociodemographic data, past and current main dietary habits and medical data were collected

146 by the investigator at inclusion. During the month after inclusion, a dietary survey was
147 performed according to the EFSA reference methodology. Parents recorded all ingesta per 24-
148 hr period over three non-consecutive days (two during the week and one during the weekend)
149 by using paper diaries, as in previous studies [26]. Investigators and on-line research
150 assistants helped parents complete the survey when needed. Dietary data from these diaries
151 were double-entered, tested for consistency, and transformed by using the ANSES-Ciquel
152 nutrient composition table for non-infant foods [27] and the infant-specific table designed for
153 the French Children's Food Union [28]. With this process, we obtained the ingesta and their
154 source for each individual and each nutrient.

155 After the dietary survey, a fasting blood sample was taken; serum ferritin (SF) and C-
156 reactive protein (CRP) were measured centrally in a unique laboratory after refrigerated
157 transport of blood samples at +2 to +8°C. SF was measured by immunochemiluminescence
158 (COBAS -Roche Diagnostics- COBAS 6000 E601, measurement range: 0.5-2000 µg/L, intra-
159 and inter-series coefficients of variation <1.1% and <5.7%, respectively) and CRP was
160 measured by immunoturbidimetric assay.

161 In case of fever or any other condition that could alter the ingesta or biological iron
162 status (e.g., bronchiolitis, gastroenteritis), the dietary survey and blood sampling were
163 postponed to 15 days after discontinuation of symptoms. Children for whom no blood sample
164 was taken, whose parents did not complete the dietary survey, or with a CRP level ≥ 10 mg/L
165 were excluded from the statistical analyses.

166

167 *Statistical analyses*

168 We first described the general characteristics of the studied and analyzed population and
169 compared them to those of the 2016 French National Perinatal Survey, a national
170 representative sample of births (n=13 148) [29]. Second, we characterized iron intake

171 specifically and its distribution considering all sources from the whole diet including YCF or
172 excluding YCF. Third, we described the distribution of SF and used multivariable linear
173 regression models (after logarithmic transformation of SF [30]) to study the crude then
174 adjusted association of SF with past dietary habits (including declared YCF consumption) and
175 current ingesta (including declared and measured YCF consumption) and perinatal and
176 sociodemographic characteristics. The specific sources of iron evaluated in the analyses are
177 listed as dietary characteristics in **Table 1**. YCF consumption was defined in several ways:
178 "any consumption after 10 months" and "current consumption at age 24 months" (two binary
179 [no/yes] declarative variables), "daily volume consumed" in five categories (measured
180 variable in the dietary record) to evaluate a "dose effect", "consumption duration" (declarative
181 variable) used as continuous variable, then in three categories to evaluate a "time effect". We
182 evaluated the duration of consumption of any IFF since age 6 months by a continuous
183 variable corresponding to the sum of consumption duration for both follow-on formula and
184 YCF. This variable represented the cumulative iron intake from dairy food at about age 6
185 months. The statistical handling of other variables is detailed in **Supplemental Methods**.
186 Finally, SF was dichotomized with a 12- $\mu\text{g/l}$ threshold to define ID, as suggested [2, 4, 31].
187 The prevalence of ID and its crude associations with potential determinants were studied by
188 univariate analysis. No multivariable analysis was used given the low number of ID cases.

189 No multi-level model was used in these analyses despite recruitment in different
190 practices because the variance of a multilevel model with random intercept including only the
191 center of recruitment was low, 7%. For all continuous variables, the lack of deviance to
192 linearity was searched and a fractional polynomial of degree 2 at most was used if
193 appropriate. Several sensitivity analyses were performed by repeating the univariate analyses
194 with a 10- $\mu\text{g/l}$ threshold of SF to define ID [2, 4, 32], repeating regressions analyses without
195 sociodemographic characteristics or studying specific associations of perinatal and

196 sociodemographic variables with iron status. Missing data ($\leq 2\%$) were not imputed. The
197 number of participants required (n=1000) was calculated with a very conservative hypothesis
198 (**Supplemental Methods**); the recruitment was stopped prematurely for financial reasons.
199 The analyses involved use of Stata/SE v13.1 (StataCorp, College Station, TX, USA).

200

201 **Results**

202 *Participants*

203 A total of 830 young children were included by 58 pediatricians from 16 French regions; 15
204 were excluded because of non-eligibility criteria, 212 (26%) because of no blood sample, 8
205 (1%) because of lack of dietary survey, 31 (5%) because of CRP level ≥ 10 mg/L, and 3
206 (0.5%) because of missing data for SF level (**Supplemental Figures 1 and 2**), leading to an
207 analyzed population of 561 infants. The analyzed population was less disadvantaged than the
208 2016 French National Perinatal Survey population but did not differ from the non-analyzed
209 population (**Supplemental Table 2**).

210 In the analyzed population, the mean age of children was 24 months (SD 0.6), 49%
211 were girls, 3.6% had cow's milk protein allergy, and 10% had received iron supplementation
212 according to parents. YCF was currently used in 73% of the population (408/561, 95%
213 confidence interval [CI] 69-76) and cow's milk in 33% (186/561, 95% CI 29-37). The mean
214 and median total iron intake for the population was 8.2 mg/day (95% CI 7.8-8.6) and 7.6
215 mg/day (interquartile range [IQR] 5.6-9.8). The mean iron intake for the population from all
216 food excluding YCF and from YCF only was 4.7 mg/day (95% CI 4.6-4.9) and 3.5 mg/day
217 (95% CI 3.1-3.8). The median iron intake for the population from all food excluding YCF and
218 from YCF only was 4.3 mg/day (IQR 3.4-5.7) and 3.1 mg/day (IQR 0-5.2). Daily iron intake
219 for the population from all food excluding YCF and total daily iron intake including YCF was

220 below the 5 mg/day AR for 63% (95% CI 59-67) and 18% (95% CI 15-22) of children
221 (**Figure 1**).

222 Median SF was 26 $\mu\text{g/L}$ (IQR: 20-37, mean: 31 [SD 21]) (**Supplemental Figure 3**).
223 After dichotomization of SF at thresholds <12 and <10 $\mu\text{g/L}$, ID prevalence was 6.6%
224 (37/561, 95% CI 4.7-9.0) and 3.9% (22/561, 95% CI 2.5-5.9) (**Table 1** and **Supplemental**
225 **Table 3**).

226

227 *Dietary factors associated with iron status*

228 On univariate analysis, SF was significantly ($p < 0.05$) lower with cow's milk use beginning
229 before age 24 months (median 23 vs 28 $\mu\text{g/L}$ if not) or its current use at 24 months (23 vs
230 28 $\mu\text{g/L}$ if not) and with increased iron intake from all food excluding YCF (β coefficient =
231 -0.03 , 95% CI -0.05 - $[-0.01]$) (**Table 1**). We found no significant association between SF and
232 exclusive breastfeeding beyond 6 months or cow's milk consumption duration (**Table 1**). SF
233 was significantly higher with follow-on formula use between age 6 and 12 months (27 vs
234 23 $\mu\text{g/L}$ if not), YCF use since age 10 months (27 vs 17 $\mu\text{g/L}$ if not) or current use at 24
235 months (29 vs 21 $\mu\text{g/L}$ if not), daily volume of YCF consumed (29 $\mu\text{g/L}$ if <100 mL/day vs
236 21 $\mu\text{g/L}$ if none), increasing YCF consumption duration (28 if > 12 months vs 17 $\mu\text{g/L}$ with
237 no YCF), and increasing IFFs consumption duration (β coefficient = 0.05, 95% CI : 0.03-
238 0.07; i.e., 28 if > 12 months vs 17 $\mu\text{g/L}$ if no IFF, this last result is not shown in Table 1)
239 (**Table 1**). For the 58 children with a high daily volume of YCF consumed (≥ 450 mL; i.e., the
240 90th percentile), we found no significant increase in mean SF level (34 vs 31 $\mu\text{mol/L}$ with
241 daily YCF volume <450 mL, $p=0.23$) or median SF level [90th percentile] (26 [51] vs 27
242 $\mu\text{mol/L}$ [58] with daily YCF <450 mL).

243 In several multivariable linear models adjusting for co-variables of interest (**Table 2**)
244 and after checking for no significant collinearity between YCF and cow's milk consumption,

245 SF was positively associated with YCF consumption, whether described by a binary variable
246 (any use after age 10 months), volume consumed or duration of consumption. SF was also
247 associated with duration of IFFs consumption since age 6 months (**Table 2**). In all
248 multivariable models, unfavorable iron status was associated with a medical history of
249 prematurity, an elevated rank among siblings and disadvantaged social situation: low father's
250 education level (**Table 2, Supplemental Table 6**) as in univariate analyses (**Supplemental**
251 **Tables 4 and 5**).

252 After dichotomizing SF at the 12- $\mu\text{g/L}$ threshold, ID was significantly associated
253 ($p < 0.05$) with the same markers as SF used as a continuous variable (**Table 1**) except iron
254 intake from all food excluding YCF. For example, ID was significantly decreased with YCF
255 use since age 10 months (25% vs 5% with YCF use, OR 0.15, 95% CI 0.07-0.31).

256 Sensitivity analyses at the 10- $\mu\text{g/L}$ threshold found a statistically significant
257 association between ID ($p < 0.05$) and the same variables as with the 12- $\mu\text{g/L}$ threshold,
258 except for infant formula use, which was significant at the 10- $\mu\text{g/L}$ threshold only
259 (**Supplemental Table 3**). Similar results were found in the sensitivity analyses for the
260 multivariate models without adjustment for sociodemographic variables comparatively to
261 those adjusted for sociodemographic variables (**Supplemental Table 6**).

262

263 **Discussion**

264 *Main results*

265 With a simultaneous collection of medical, biological and dietary data at the national scale, a
266 design rarely achieved in the literature [23, 24], we found a protective role of YCF use on ID
267 in children at age two years in the general population. This protective role was strong with,
268 for example, a reduction of one-fifth of ID with YCF use since age 10 months (OR 0.15, 95%
269 CI 0.07-0.31). This protective role was consistent according to the different definitions of

270 YCF consumption (amount, duration), measured either retrospectively by asking parents
271 about the past consumption or prospectively by quantifying current consumption with a
272 dietary survey. This protective role is consistent with results from clinical trials [11-17] and
273 previous observational studies [23-25, 33] and was independent of potential confounders such
274 as disadvantaged social situation, non-dairy iron intake and iron supplementation, which were
275 not always taken into account in previous studies [23, 24]. This protective role is easy to
276 conceive theoretically because iron given to young children in any form is supposed to
277 increase their iron stores in the absence of concurrent loss or illness, given the almost closed-
278 circuit metabolism of iron [4, 31, 34, 35].

279 Our study provides information on how YCF-based strategies could help improve iron
280 status in the general population. First, the mean total iron intake was 8.2 mg/day, higher than
281 the 5 mg/day AR recommended in Europe by the EFSA, in 82% of children [6]. The mean
282 intake from all sources excluding YCF was 4.7 mg/day and from YCF only was 3.5 mg/day
283 for the population analyzed. Added to the EFSA recommended strategy based on naturally
284 iron-rich food, YCF use allowed for a reduction from 63% to 18% of children with below the
285 5-mg/day AR. Thus, YCF use added to the rest of the diet allowed 45% of children to reach
286 the daily AR. Furthermore, the YCF impact on iron status was detectable even for a small
287 daily volume consumed, but the increase >500 mL/day was not associated with a significant
288 increase in SF. Results from several studies support that a small volume of YCF (100–300
289 mL/day) allows for reaching the recommended AR [36-38]. Iron bioavailability mechanisms
290 are complex, and the amount of iron ingested is not equal to the amount of iron absorbed.
291 This absorption depends notably on the origin of iron (haem or not), the type of other
292 concomitant ingested food and the period of life, notably acceleration of growth [2-4, 31, 39].
293 Thus, even a small amount of iron with IFFs could improve iron status [40, 41].

294 Second, another finding helps in understanding how YCF use could help improve iron
295 status: the association observed between increased SF and consumption duration of IFFs since
296 age 6 months (i.e., follow-on formula, then YCF). This "time effect" implying the duration of
297 exposure to IFFs suggests a role of long-term, "cumulative", consumption of IFFs in iron
298 status at age 24 months. This finding, as the previous one about a non-linear effect of YCF
299 volume consumed on iron status, can probably be explained in part by the role of hepcidin in
300 regulating iron absorption and the prevention of iron overload if iron reserves are already
301 high. Indeed, this peptide synthesized by hepatocytes participates in regulating iron absorption
302 by enterocytes: when iron reserves are high, hepcidin synthesis increases and induces the
303 degradation of ferroportin on enterocytes and macrophage membranes, thus limiting iron
304 release in blood circulation [35, 39, 42], whereas when iron reserves are low, hepcidin
305 synthesis is downregulated, thereby increasing iron bioavailability. The potential risk of iron
306 excess with fortification use can be raised. Use of IFFs has been found associated with iron
307 intake above the tolerable upper intake level but not excess iron stores based on SF
308 distribution in infants [38, 43]. In our analyzed population, we found no significant difference
309 in SF distribution with high daily volume consumed. This study suggests that small amounts
310 of iron ingested regularly over time could be more beneficial to prevent ID than high amounts
311 over a short period without leading to iron excess stores.

312 In this study, we found other determinants of iron status at 24 months usually
313 identified in the literature: medical history of prematurity and factors linked to deprived
314 situation (low father's education level) or family situation (high rank in siblings). The
315 independent association found between iron status and a history of prematurity, remaining
316 even after taking into account iron supplementation, suggests that this sub-population at high
317 risk of ID should benefit from more specific prevention and monitoring of iron status, as
318 previously found [44, 45]. "Exclusive" breastfeeding beyond 6 months is a classical risk

319 factor for ID [46], but it was not independently associated with iron status in our study,
320 probably because assessment of iron status occurred late, at 24 months, and many other
321 nutritional factors may have intervened between 7 and 24 months.

322

323 *Strengths and limitations*

324 Our study has several strengths. The measurements of iron biomarkers were standardized and
325 centralized as recommended by the World Health Organization [47], as was the evaluation of
326 nutritional intake with a dietary survey performed on three non-consecutive days to improve
327 the accuracy of intra-individual variability, as recommended by the EFSA [26]. Biological
328 and dietary data were measured independently, with blinding. A specific strength of this study
329 is the consideration of all sources of iron besides YCF in multivariate analyses in contrast to
330 some other national studies [23, 24].

331 There were several limitations. First, the analyzed population presented a selection
332 bias as shown by less frequent disadvantaged situations than in all births. This bias can be
333 explained mainly by recruitment by pediatricians and the significant attrition due notably to
334 failure to obtain a blood sample (32% of the studied population). Indeed, only 20% of French
335 children at age 24 months are followed by a pediatrician [48] and those who accepted to
336 participate in this complex study were probably familiar with clinical research. The study
337 possibly selected families interested in the topic of nutrition with good knowledge and
338 practices regarding ID prevention. This selection bias probably led to underestimating the ID
339 prevalence, which was regardless close to the most recent national estimations [49].
340 Furthermore, this potential bias could not have altered the associations between iron status
341 and YCF consumption in the analyzed children. Second, the recruitment was stopped before
342 the calculated sample size was achieved, and the attrition may have led to loss of statistical
343 power. However, the sample size was calculated on the basis of a very conservative

344 hypotheses on expected associations that were not confirmed by the study (associations were
345 much stronger than expected). To manage the lack of power, the main analyses were finally
346 based on ID defined by SF level as a continuous variable. Finally, as in other studies, some
347 inaccuracies may have occurred during the declarative food intake data collected by the
348 pediatrician and regarding the quantities assessed by the parents during the survey. However,
349 they may have been limited by the checks of a well-trained dietician as detailed in
350 **Supplemental Methods**. Besides, these inaccuracies occurred with blinding to iron status, so
351 they may have led to only a non-differential bias and a loss of statistical power.

352

353 *Implications*

354 In this first national-level study taking into account non-dairy iron intake and iron
355 supplementation and the family's socio-economic status, YCF consumption allowed for
356 reaching the required iron AR in 45% of children who were not reaching it otherwise by
357 dietary intake. YCF use was strongly and independently associated with better iron status than
358 non-use. The biological benefit of YCF was obtained even for a limited daily amount, about
359 200 mL/day, especially when implemented over a long period. These findings support
360 national strategies for ID prevention based on the recommendation for YCF consumption
361 after age 12 months [7, 8]. YCF consumption seems a simple way to supply young children
362 with the recommended iron intake and reach the recommended AR added to the rest of the
363 diet in practice, according to the family's and country's culture. Indeed, a well-balanced diet
364 by solid food is possibly difficult to achieve at this age [9, 10]. These findings should trigger
365 measures to enhance YCF accessibility to at-risk families (i.e., those in disadvantaged
366 situations).

367

368 Acknowledgments

369 The authors thank URC-CIC Paris Descartes Necker Cochin (project manager: Nelly Briand
370 and clinical research associates: Camille Boucheny, Charlène Ambvouli and Emilie Le Roux)
371 for the implementation and monitoring of the study. The authors thank ACTIV network
372 clinical research associates: Claire Prieur, Deborah Kern. They thank the participant families
373 and the pediatricians who recruited them:

374 Jean-Marie André, Pierre Bakhache, Sophie Barrois, Bénédicte Blanc, Marie-Emmanuelle
375 Bouloumié, Fabienne Cahn-Sellem, Marie-Hélène Cavert, Anne Cheve, Christian Copin,
376 Muriel Cornic, François Corrad, Armelle Courboin, Véronique Dagrenat, Caroline De
377 Backer, Pascal Dechelette, Jean-François Delobbe, Michèle Dudreuilh, Corinne Dumas,
378 Christine Duvant-Fay, Annie Elbez, Chantal Gayot, Nathalie Gelbert, Patricia Giraud-
379 Escoffier, Geneviève Granat, Cécile Guiheneuf, Frédéric Hassid, Kai Kassmann, Sylvie
380 Labarge, Sophie Langlais, Hélène Le Scornet, Dominique Lemarié, Claudia Litzler, Christine
381 Magendie, Delphine Menet, Bénédicte Nold, Jean- Claude Oilleau, France Paratte, Brigitte
382 Pinçant, Sophie Ravilly, Olivier Romain, Bechara Saade, Catherine Salinier, Claire Sarreau,
383 Ruth-Caroline Schweitzer, Anne Sengier-Njinou, Philippe Simon, David Somerville, Joachim
384 Stoller, Marie-Pierre Streicher, Catherine Tuberg-Romain, Jean-Christophe Vigreux, Pascale
385 Vurpillat-Almanza, Andreas Werner, Alain Wollner, Morched Zouari.

386

387 Sources of funding:

388 This work was supported by Paris Diderot University - Sorbonne Paris Cité for a doctoral
389 grant for Dr. AS Sacri, Secteur Français des Aliments de l'Enfance, and the French Ministry
390 of Health ["DGOS PHRC régional 2014 no. AOR14053"]. The sponsor was Assistance
391 Publique – Hôpitaux de Paris (Délégation à la Recherche Clinique et à l'Innovation [DRCI]).

392

393 **Conflict of interest statement:**

394 The funders had no role in the study design, data collection and analysis, decision to publish,
395 or preparation of the manuscript. The authors have no patents, products in development or
396 marketed products to declare.

397

398 **References**

- 399 1. Lozoff B, Jimenez E, Wolf AW. Long-term developmental outcome of infants with
400 iron deficiency. *N Engl J Med* 1991;325: 687-694.
- 401 2. Baker RD, Greer FR. Diagnosis and prevention of iron deficiency and iron-deficiency
402 anemia in infants and young children (0-3 years of age). *Pediatrics* 2010;126: 1040-1050.
- 403 3. EFSA. European Food Security Authority. Panel on Dietetic Products, Nutrition and
404 Allergies (NDA). Scientific Opinion on nutrient requirements and dietary intakes of infants
405 and young children in the European Union. *European Food Security Authority (EFSA)*
406 *Journal* [serial online] 2013;11: 3408-3511.
- 407 4. Domellof M, Braegger C, Campoy C, Colomb V, Decsi T, Fewtrell M, et al. Iron
408 requirements of infants and toddlers. *J Pediatr Gastroenterol Nutr* 2014;58: 119-129.
- 409 5. Ghisolfi J, Vidailhet M, Fantino M, Bocquet A, Bresson JL, Briend A, et al. Lait de
410 vache ou lait de croissance : quel lait recommander pour les enfants en bas age (1-3 ans) ?
411 [French]. *Arch Pediatr* 2011;18: 355-358.
- 412 6. EFSA. Dietary reference values for nutrients: Summary report. EFSA supporting
413 publication 2017: published online Dec 8. DOI: 10.2903/sp.efsa.2017.e15121. (Available
414 from: <https://www.efsa.europa.eu/en/supporting/pub/e15121>.)
- 415 7. 'Growing-up' formula: No additional value to a balanced diet, says EFSA. Parma:
416 European Food Safety Authority (EFSA), 2013. (Accessed November 2018, at:
417 <https://www.efsa.europa.eu/en/press/news/131025>.)
- 418 8. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion
419 on nutrient requirements and dietary intakes of infants and young children in the European
420 Union. *EFSA Journal* 2013: published online Oct 25. DOI: 10.2903/j.efsa.2013.3408.
421 (Available from: <https://www.efsa.europa.eu/en/efsajournal/pub/3408>.)


- 422 9. Chouraqui JP, Tavoularis G, Simeoni U, Ferry C, Turck D. Food, water, energy, and
423 macronutrient intake of non-breastfed infants and young children (0-3 years). *Eur J Nutr*
424 2019.
- 425 10. Grimes CA, Szymlek-Gay EA, Campbell KJ, Nicklas TA. Food Sources of Total
426 Energy and Nutrients among U.S. Infants and Toddlers: National Health and Nutrition
427 Examination Survey 2005-2012. *Nutrients* 2015;7: 6797-6836.
- 428 11. Fuchs GJ, Farris RP, DeWier M, Hutchinson SW, Warriar R, Doucet H, et al. Iron
429 status and intake of older infants fed formula vs cow milk with cereal. *Am J Clin Nutr*
430 1993;58: 343-348.
- 431 12. Moffatt ME, Longstaffe S, Besant J, Dureski C. Prevention of iron deficiency and
432 psychomotor decline in high-risk infants through use of iron-fortified infant formula: a
433 randomized clinical trial. *J Pediatr* 1994;125: 527-534.
- 434 13. Daly A, MacDonald A, Aukett A, Williams J, Wolf A, Davidson J, et al. Prevention of
435 anaemia in inner city toddlers by an iron supplemented cows' milk formula. *Arch Dis Child*
436 1996;75: 9-16.
- 437 14. Gill DG, Vincent S, Segal DS. Follow-on formula in the prevention of iron deficiency:
438 a multicentre study. *Acta Paediatr* 1997;86: 683-689.
- 439 15. Morley R, Abbott R, Fairweather-Tait S, MacFadyen U, Stephenson T, Lucas A. Iron
440 fortified follow on formula from 9 to 18 months improves iron status but not development or
441 growth: a randomised trial. *Arch Dis Child* 1999;81: 247-252.
- 442 16. Maldonado Lozano J, Baro L, Ramirez-Tortosa MC, Gil F, Linde J, Lopez-Huertas E,
443 et al. [Intake of an iron-supplemented milk formula as a preventive measure to avoid low iron
444 status in 1-3 year-olds]. *An Pediatr (Barc)* 2007;66: 591-596.
- 445 17. Akkermans MD, Eussen SR, van der Horst-Graat JM, van Elburg RM, van Goudoever
446 JB, Brus F. A micronutrient-fortified young-child formula improves the iron and vitamin D

- 447 status of healthy young European children: a randomized, double-blind controlled trial. *Am J*
448 *Clin Nutr* 2017;105: 391-399.
- 449 18. Attree P. A critical analysis of UK public health policies in relation to diet and
450 nutrition in low-income households. *Matern Child Nutr* 2006;2: 67-78.
- 451 19. Barker D, Barker M, Fleming T, Lampl M. Developmental biology: Support mothers
452 to secure future public health. *Nature* 2013;504: 209-211.
- 453 20. Fleurbaey M, Luchini S, Schokkaert E, Van de Voorde C. Évaluation des politiques de
454 santé : pour une prise en compte équitable des intérêts des populations. *Economie et*
455 *Statistique / Economics and Statistics - Insee* 2012;455-456.
- 456 21. Méthodes d'évaluation des politiques publiques - actes du séminaire [séminaire
457 Dress]. Paris, France: Ministère des Solidarités et de la Santé, 2011. (Accessed May 2019, at:
458 [http://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/recueils-ouvrages-et-](http://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/recueils-ouvrages-et-rapports/ouvrages-thematiques/article/methodes-d-evaluation-des-politiques-publiques-actes-du-seminaire)
459 [rapports/ouvrages-thematiques/article/methodes-d-evaluation-des-politiques-publiques-actes-](http://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/recueils-ouvrages-et-rapports/ouvrages-thematiques/article/methodes-d-evaluation-des-politiques-publiques-actes-du-seminaire)
460 [du-seminaire.](http://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/recueils-ouvrages-et-rapports/ouvrages-thematiques/article/methodes-d-evaluation-des-politiques-publiques-actes-du-seminaire))
- 461 22. Sacri AS, Hercberg S, Gouya L, Levy C, Bocquet A, Blondel B, et al. Very low
462 prevalence of iron deficiency among young French children: A national cross-sectional
463 hospital-based survey. *Matern Child Nutr* 2017 May 03. doi: 10.1111/mcn.12460. [Epub
464 ahead of print].
- 465 23. Sidnell A, Pigat S, Gibson S, O'Connor R, Connolly A, Sterecka S, et al. Nutrient
466 intakes and iron and vitamin D status differ depending on main milk consumed by UK
467 children aged 12-18 months - secondary analysis from the Diet and Nutrition Survey of
468 Infants and Young Children. *J Nutr Sci* 2016;5: e32.
- 469 24. Uijterschout L, Vloemans J, Vos R, Teunisse PP, Hudig C, Bubbers S, et al.
470 Prevalence and risk factors of iron deficiency in healthy young children in the southwestern
471 Netherlands. *J Pediatr Gastroenterol Nutr* 2014;58: 193-198.

- 472 25. McCarthy EK, Ni Chaoimh C, Hourihane JO, Kenny LC, Irvine AD, Murray DM, et
473 al. Iron intakes and status of 2-year-old children in the Cork BASELINE Birth Cohort Study.
474 *Matern Child Nutr* 2017;13.
- 475 26. EFSA. General principles for the collection of national food consumption data in the
476 view of a pan-European dietary survey. *EFSA Journal* 2009;7.
- 477 27. Table de composition nutritionnelle des aliments Ciqua [Internet database]. Agence
478 nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (Anses),
479 2017. (Accessed January 2018, at: <https://ciqua.anses.fr/>.)
- 480 28. Tavoularis G. Nutri-Bebe 2013 Study Part 1. Presentation and methodological
481 considerations. *Arch Pediatr* 2015;22: 10s11-16.
- 482 29. Blondel B, Coulm B, Bonnet C, Goffinet F, Le Ray C, National Coordination Group
483 of the National Perinatal S. Trends in perinatal health in metropolitan France from 1995 to
484 2016: Results from the French National Perinatal Surveys. *J Gynecol Obstet Hum Reprod*
485 2017;46: 701-713.
- 486 30. Bland JM, Altman DG. Transformations, means, and confidence intervals. *BMJ*
487 1996;312: 1079.
- 488 31. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. *Lancet* 2007;370: 511-520.
- 489 32. Dallman PR, Siimes MA, Stekel A. Iron deficiency in infancy and childhood. *Am J*
490 *Clin Nutr* 1980;33: 86-118.
- 491 33. Vincelet C, Foucault C. [Measuring iron levels relative to the type of milk consumed
492 within a population of 16 to 18 month old French infants]. *Sante Publique* 2005;17: 339-346.
- 493 34. de Montalembert M, Bresson JL, Brouzes C, Ruemmele FM, Puy H, Beaumont C.
494 [Diagnosis of hypochromic microcytic anemia in children]. *Arch Pediatr* 2012;19: 295-304.

- 495 35. Loreal O, Bardou-Jacquet E, Jouanolle AM, Gandon Y, Deugnier Y, Brissot P, et al.
496 [Iron metabolism and tools for the iron status assessment]. *Rev Med Interne* 2012;33 Suppl 1:
497 S3-9.
- 498 36. Walton J, Flynn A. Nutritional adequacy of diets containing growing up milks or
499 unfortified cow's milk in Irish children (aged 12-24 months). *Food Nutr Res* 2013;57.
- 500 37. Ghisolfi J, Fantino M, Turck D, de Courcy GP, Vidailhet M. Nutrient intakes of
501 children aged 1-2 years as a function of milk consumption, cows' milk or growing-up milk.
502 *Public Health Nutr* 2013;16: 524-534.
- 503 38. Eussen SR, Pean J, Olivier L, Delaere F, Lluch A. Theoretical Impact of Replacing
504 Whole Cow's Milk by Young-Child Formula on Nutrient Intakes of UK Young Children:
505 Results of a Simulation Study. *Ann Nutr Metab* 2015;67: 247-256.
- 506 39. de Montalembert M, Bresson J, Brouzes C, Ruemmele F, Puy H, Beaumont C.
507 Exploration d'une anemie microcytaire chez l'enfant. *Arch Pediatr* 2012;19: 295-304.
- 508 40. Fomon SJ, Ziegler EE, Serfass RE, Nelson SE, Frantz JA. Erythrocyte incorporation
509 of iron is similar in infants fed formulas fortified with 12 mg/L or 8 mg/L of iron. *J Nutr*
510 1997;127: 83-88.
- 511 41. Walter T, Pino P, Pizarro F, Lozoff B. Prevention of iron-deficiency anemia:
512 comparison of high- and low-iron formulas in term healthy infants after six months of life. *J*
513 *Pediatr* 1998;132: 635-640.
- 514 42. Ganz T. Heparin and iron regulation, 10 years later. *Blood* 2011;117: 4425-4433.
- 515 43. van der Merwe LF, Eussen SR. Iron status of young children in Europe. *Am J Clin*
516 *Nutr* 2017;106: 1663S-1671S.
- 517 44. McCarthy EK, Dempsey EM, Kiely ME. Iron supplementation in preterm and low-
518 birth-weight infants: a systematic review of intervention studies. *Nutr Rev* 2019;77: 865-877.

- 519 45. Akkermans MD, Uijterschout L, Abbink M, Vos P, Rovekamp-Abels L, Boersma B,
520 et al. Predictive factors of iron depletion in late preterm infants at the postnatal age of 6
521 weeks. *Eur J Clin Nutr* 2016;70: 941-946.
- 522 46. Atkins LA, McNaughton SA, Campbell KJ, Szymlek-Gay EA. Iron intakes of
523 Australian infants and toddlers: findings from the Melbourne Infant Feeding, Activity and
524 Nutrition Trial (InFANT) Program. *Br J Nutr* 2016;115: 285-293.
- 525 47. Iron deficiency anaemia. Assessment, prevention and control. A guide for programme
526 managers. Geneva: World Health Organization (WHO), 2001. (Accessed December 2019, at:
527 http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf.)
- 528 48. Bocquet A, Chalumeau M, Bollotte D, Escano G, Langue J, Virey B. [Comparison of
529 prescriptions by pediatricians and general practitioners: a population-based study in Franche-
530 Comte from the database of Regional Health Insurance Fund]. *Arch Pediatr* 2005;12: 1688-
531 1696.
- 532 49. Sacri AS, Hercberg S, Gouya L, Levy C, Bocquet A, Blondel B, et al. Very low
533 prevalence of iron deficiency among young French children: A national cross-sectional
534 hospital-based survey. *Matern Child Nutr* 2018;14.
- 535 50. Cochrane Handbook for Systematic Reviews of Interventions. London: The Cochrane
536 Collaboration, 2011. (Accessed June 2018, at: [https://www.cochrane.org/news/new-](https://www.cochrane.org/news/new-cochrane-handbook-systematic-reviews-interventions)
537 [cochrane-handbook-systematic-reviews-interventions](https://www.cochrane.org/news/new-cochrane-handbook-systematic-reviews-interventions).)
- 538 51. Chouraqui JP, Turck D, Tavoularis G, Ferry C, Dupont C. The Role of Young Child
539 Formula in Ensuring a Balanced Diet in Young Children (1-3 Years Old). *Nutrients* 2019;11.
- 540 52. World Economic and Financial Surveys: World Economic Outlook Database.
541 Washington, D.C.: International Monetary Fund Research Dept., 2017. (Accessed September
542 2019, at: <http://www.imf.org/external/pubs/ft/weo/2016/02/weodata/index.aspx>.)



5

545 **Figure 1.** Distribution of mean daily iron intake (mg/day) according to deciles and quartiles
 546 of iron intake stratified by iron sources (n=561): from all food (red line), from all food
 547 excluding young-child formula (YCF, blue line), and YCF only (green line).

548 Deciles and quartiles were calculated separately by iron sources. At a consequence, for each
 549 decile or quartile, mean daily iron intake from all food is not equal to the addition of mean
 550 daily iron intake from all food excluding YCF + YCF only.

551 In children who did not reached the required iron average requirements recommended from
 552 all food without YCF, 45% reached this threshold if iron intake from YCF was considered.

553 Horizontal orange line: threshold of iron intake of 5 mg/day corresponding to the average
 554 requirements recommended by the European Food Security and Authority (EFSA) at age 24
 555 months [6]

556

557

558 **Table 1.** Dietary characteristics of children and univariate associations with serum ferritin
 559 level and iron deficiency (ID) at a threshold of 12 µg/L (by milk according to the age of
 560 consumption)

561

Characteristics	n (%) ^a	Serum ferritin level (µg/L)			ID, serum ferritin level < 12 µg/L			
		Median ^b	IQR ^b	p ^c	ID ^a (%)	No ID ^a (%)	OR ^d	95% CI ^e
	n = 561				n = 37	n = 524		
“Exclusive” breastfeeding > 6 months								
No	484 (86)	27	20-37	-	5	95	-	-
Yes	77 (14)	26	17-35	0.07	16	84	3.39	1.62-7.07
Infant formula: consumption 0 to 6 months								
No	128 (23)	26	19-35	-	10	90	-	-
Yes	433 (77)	27	20-37	0.11	6	94	0.52	0.26-1.05
Late food diversification > 6 months								
No	546 (98)	26	20-37	-	7	93	-	-
Yes	10 (2)	30	23-38	0.83	10	90	1.57	0.19-12.77
Follow-on formula: consumption 6 to 10-12 months								
No	68 (12)	23	15-35	-	21	79	-	-
Yes	492 (88)	27	20-37	<0.01	5	95	0.19	0.09-0.39
Follow-on formula: consumption duration (months)^f								
	5.7 (1.5)	0.01	-0.03-0.04	0.65	5.8 (1.7)	5.7 (1.4)	1.05	0.80-1.37
YCF: consumption after 10 months								
No	48 (9)	17	11-30	-	25	75	-	-
Yes	512 (91)	27	21-37	<0.001	5	95	0.15	0.07-0.31
YCF: current consumption at 24 months								
No	153 (27)	21	14-29	-	18	82	-	-
Yes	408 (73)	29	22-40	<0.001	2	98	0.10	0.05-0.22
Current YCF: daily volume consumed								
No consumption	150 (27)	21	14-30	-	18	82	-	-
< 100 mL / day	175 (31)	29	22-43	<0.001	1	99	0.05	0.01-0.23
100-300 mL / day	103 (18)	28	21-35	<0.001	7	93	0.33	0.14-0.80
300-500 mL / day	101 (18)	30	21-40	<0.001	1	99	0.05	0.01-0.34
≥ 500 mL / day	32 (6)	27	22-42	<0.001	0	100	0.14	0.01-0.91
YCF: consumption duration (months)^f								
	11.3 (3.0)	0.04	0.02-0.05	<0.001	8.5 (4.7)	11.4 (2.9)	0.82	0.74-0.90
YCF: consumption duration								
No consumption	48 (9)	17	11-30	-	27	73	-	-
≤ 6 months	61 (11)	21	14-34	0.09	15	85	0.47	0.18-1.21
> 6 and ≤ 12 months	235 (44)	27	21-36	<0.001	3	97	0.08	0.03-0.22
> 12 months	197 (36)	28	21-41	<0.001	3	97	0.08	0.03-0.24
IFFs: consumption (since age 6 months) duration (months)^f								
	15.3 (5.3)	0.05	0.03-0.07	<0.001	8.9 (7.3)	15.8 (4.8)	0.85	0.81-0.89
Cow's milk: consumption beginning before 24 months								
No	356 (64)	28	21-40	-	3	97	-	-
Yes	201 (36)	23	15-34	<0.001	13	87	5.98	2.75-13.00
Cow's milk: current consumption at 24 months								
No	375 (67)	28	21-39	-	3	97	-	-
Yes	186 (33)	23	16-35	<0.001	14	86	5.38	2.59-11.15
Cow's milk: consumption duration (months)^f								
	7.4 (4.4)	-0.01	-0.04-0.01	0.15	9.4 (4.7)	7.1 (4.3)	1.13	1.02-1.25
Dietary iron intake from all food excluding YCF^f (mg/day)								
	4.7 (2.2)	-0.03	-0.05-(-0.01)	0.01	5.2 (2.8)	4.7 (2.2)	1.10	0.96-1.25
Iron supplementation since birth^g								
No	503 (90)	26	20-36	-	7	93	-	-
Yes	57 (10)	29	22-41	0.17	4	96	0.49	0.11-2.08

562

^a or mean (SD) if the “characteristics” variable is continuous

563

^b or β coefficient of a simple linear regression after logarithmic transformation (instead of medians) and 95% confidence interval (CI), instead of interquartile range [IQR]) if the « characteristics » variable is continuous

564

565

^c Degree of significance of the Student test, Kruskal-Wallis test or of the β coefficient of a simple linear regression (univariable analyses

566

after a logarithmic transformation of the dependent variable: serum ferritin level)

567

^d For cells with a zero value, 1 was added to all values of the contingency table as suggested [50]

568

^e 95% CI of odds ratio (OR) in multivariable analyses

569

^f no deviance to linearity in the linear model or the univariate logistic regression model

570

^g no change in the results taking into account time interval between iron supplementation and serum ferritin level measure

571

572

Abbreviations: IFF = iron fortified formula, YCF = young-child formula

573

574

575 **Table 2.** Adjusted analyses of associations between serum ferritin level and young-child
 576 formula (YCF) consumption, other dietary, perinatal and sociodemographic characteristics
 577

Characteristics	n (%) ^a	Serum ferritin level (µg/L)							
		β ^b	95% CI ^f	β ^c	95% CI ^f	β ^d	95% CI ^f	β ^e	95% CI ^f
YCF considering different definitions									
Consumption of YCF after 10 months									
No	48 (9)	-	-	-	-	-	-	-	-
Yes	512 (91)	0.28	0.12-0.45	-	-	-	-	-	-
Daily volume of YCF consumed (mL/day)									
No YCF	150 (27)	-	-	-	-	-	-	-	-
< 100	175 (31)	-	-	0.34	0.20-0.47	-	-	-	-
100-300	103 (18)	-	-	0.25	0.10-0.39	-	-	-	-
300-500	101 (18)	-	-	0.33	0.18-0.48	-	-	-	-
≥ 500	32 (6)	-	-	0.39	0.17-0.60	-	-	-	-
YCF consumption duration (months)^g									
	11.3 (3.0)	-	-	-	-	0.03	0.01-0.04	-	-
Duration of consumption of IFFs (since age 6 months)^g									
	15.3 (5.3)	-	-	-	-	-	-	0.03	0.01-0.06
Other dietary characteristics									
« Exclusive » breastfeeding > 6 months									
No	484 (86)	-	-	-	-	-	-	-	-
Yes	77 (14)	-0.08	-0.21-0.06	-0.12	-0.24-0.02	0.04	-0.11-0.18	0.06	-0.08-0.21
Late food diversification > 6 months									
No	546 (98)	-	-	-	-	-	-	-	-
Yes	10 (2)	0.13	-0.21-0.46	0.13	-0.20-0.46	0.07	-0.31-0.45	0.14	-0.18-0.47
Cow's milk consumption beginning before 24 months									
No	356 (64)	-	-	-	-	-	-	-	-
Yes	201 (36)	-0.17	-0.26-(-0.07)	-0.05	-0.16-0.07	-0.12	-0.23-(-0.01)	-0.12	-0.22-0.01
Dietary iron intake from all food excluding YCF^h (mg/day)									
Continuous	4.7 (2.2)	-	-	-	-	-	-	-	-
< 3.5	161 (29)	-	-	-	-	-	-	-	-
3.5–7	337 (60)	-0.05 ^h	-0.21-0.12	-0.06 ^h	-0.22-0.11	-0.06	-0.17-0.04	-0.06	-0.16-0.04
7–10.5	48 (9)	-0.10 ^h	-0.29-0.10	-0.11 ^h	-0.30-0.09	-0.01	-0.19-0.17	-0.02	-0.19-0.15
≥ 10.5	15 (3)	-0.12 ^h	-0.32-0.09	-0.13 ^h	-0.33-0.07	-0.17	-0.51-0.16	-0.16	-0.46-0.14
Iron supplementation since birthⁱ									
No	503 (90)	-	-	-	-	-	-	-	-
Yes	57 (10)	0.13	-0.03-0.29	0.14	-0.02-0.29	0.13	-0.03-0.29	0.14	-0.02-0.30

578

579 ^a or mean (SD) if the “characteristics” variable is continuous

580 All the following multivariable linear models were adjusted on YCF consumption (considering different methods of coding, cf. notes below),
 581 exclusive breastfeeding > 6 months, late food diversification > 6 months, cow's milk consumption, dietary iron intake excluding YCF, iron
 582 supplementation, sex, prematurity, birth weight < 2500 g, rank in siblings, country of birth, education level, and unemployment of parents,
 583 family having a health coverage fully funded publicly. The dependent variable “serum ferritin level” underwent a logarithmic transformation.

584 ^b β coefficient of a multiple linear regression model using the binary variable YCF formula consumption (no/yes)585 ^c β coefficient of a multiple linear regression model using the variable daily volume of YCF consumed586 ^d β coefficient of a multiple linear regression model using the variable duration of consumption of YCF only587 ^e β coefficient of a multiple linear regression model using the variable duration of consumption of iron-fortified formula since 6 months-old588 ^f 95% CI of the β coefficient of a multiple linear regression model corresponding589 ^g no deviance to linearity590 ^h creation of a fractional polynomial degree 2 for this variable in a few models because of deviance to linearity (as shown by italics). Results
 591 for dietary iron intake excluding YCF are presented by categories for ease of reading592 ⁱ no change in the results taking into account time interval between iron supplementation and serum ferritin level measure

593

594 Perinatal and sociodemographic variables in these models are not shown: in all models a lower SF was independently associated with a
 595 medical history of prematurity, a high rank in siblings, and a low father's education level

596

597 Abbreviations: CI = confidence interval, IFF = iron fortified formula

598

599